(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) jumped by a staggering 23.78% in 10 sessions from $0.35 at 2023-03-13, to $0.43 at 20:27 EST on Sunday, after five sequential sessions in a row of gains. NASDAQ is dropping 0.74% to $11,630.51, following the last session’s downward trend.
Xenetic Biosciences’s last close was $0.43, 65.61% below its 52-week high of $1.25.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
Yearly Top and Bottom Value
Xenetic Biosciences’s stock is valued at $0.43 at 20:27 EST, way under its 52-week high of $1.25 and way higher than its 52-week low of $0.24.
Sales Growth
Xenetic Biosciences’s sales growth for the current quarter is negative 39.9%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 1.55M for the twelve trailing months.
More news about Xenetic Biosciences (XBIO).
